Effects of dual initial combination therapy with macitentan plus riociguat or macitentan plus selexipag on hemodynamics in patients with pulmonary arterial hypertensio
Not Applicable
Recruiting
- Conditions
- Pulmonary arterial hypertension
- Registration Number
- JPRN-UMIN000035389
- Lead Sponsor
- Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 76
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients without PAH 2) Patients treated with PAH-specific drugs 3) Patients treated with incompatible drug combination 4) Patients with bleeding or risk of bleeding 5) Patients with pregnancy or suspected pregnancy or patients with breast-feeding 6) Patients with atrial fibrillation 7) Patients with moderate renal dysfunction (serum creatinine 1.5 mg/dl) 8) Patients with moderate liver dysfunction (serum AST or ALT 2-fold of standard value)9) Patients with hypotension (systolic blood pressure less than 90 mmHg) 10) Patients with low cardiac output (cardiac index less than 2.0 l/min/m2 11) Patients included other clinical study 12) Patients recognized as inappropriate by attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of change ratio of pulmonary vascular resistance eight month after the administration between two groups
- Secondary Outcome Measures
Name Time Method